Semaglutide·Novo Nordisk·Oral tablet

Oral Wegovy

Oral Wegovy® (oral semaglutide for chronic weight management) is an FDA-approved once-daily semaglutide tablet manufactured by Novo Nordisk, FDA-approved in 2025 for chronic weight management in eligible adults. It is taken once daily at the 25mg or 50mg dose. Weight Method does not dispense or prescribe brand-name Oral Wegovy®. Our prescribing providers issue patient-specific prescriptions for compounded semaglutide, dispensed by U.S.-licensed 503A compounding pharmacies. Compounded semaglutide is not FDA-approved.

25mg50mgOnce daily
Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Oral Wegovy is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated June 2026Medically reviewed by licensed providers

Oral Wegovy (semaglutide) is an FDA-approved GLP-1 medication for weight loss; in trials of the brand-name product, patients lost an average of 15-22% of their body weight. Weight Method does not dispense brand-name Oral Wegovy — it offers compounded semaglutide, prescribed by licensed providers, from $199/month with virtual consultations and direct shipping.

Key Fact

Oral Wegovy® is an FDA-approved once-daily oral semaglutide tablet manufactured by Novo Nordisk for chronic weight management. It is taken once daily at the 25mg or 50mg dose.

Source: FDA approval data — Oral Wegovy® prescribing information

How does this medication work?

Oral Wegovy delivers high-dose semaglutide (25-50mg) via daily tablet, activating GLP-1 receptors to suppress appetite and slow digestion.

Oral Wegovy uses a next-generation oral formulation that delivers semaglutide at significantly higher doses (25mg and 50mg) than the earlier oral semaglutide product Rybelsus (which maxes out at 14mg). Like all semaglutide products, it activates GLP-1 receptors in the brain to suppress appetite, reduce cravings, and slow gastric emptying. The higher oral doses in Oral Wegovy achieve systemic semaglutide exposure comparable to the 2.4mg injectable Wegovy dose, which is why it produces similar weight loss results. The tablet uses advanced absorption-enhancing technology to ensure adequate bioavailability despite oral administration.

What is it FDA-approved for?

FDA-approved for chronic weight management (2025), the first oral GLP-1 medication approved specifically for weight loss. A daily-tablet alternative to injectable therapy.

Oral Wegovy is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial BMI of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) with at least one weight-related comorbidity. It received FDA approval in 2025 based on the OASIS clinical trial program, which demonstrated that oral semaglutide at the 50mg dose produced weight loss on par with injectable semaglutide 2.4mg. This makes Oral Wegovy the first oral medication to match the efficacy of injectable GLP-1 therapy for weight loss.

What are the key facts you should know?

Daily oral tablet at 25mg or 50mg, FDA-approved for chronic weight management, taken on empty stomach, next-gen absorption technology, manufactured by Novo Nordisk.

Oral Wegovy is available in two dose strengths: 25mg and 50mg, taken once daily. It is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in eligible adults. The medication is taken on an empty stomach with a small amount of water, similar to Rybelsus. Novo Nordisk developed the higher-dose oral formulation as a once-daily alternative to lower-dose oral semaglutide.

Why choose this treatment?

Oral Wegovy offers a daily-pill route for patients who prefer to avoid injections, FDA-approved specifically for chronic weight management.

Oral Wegovy® is the FDA-approved oral semaglutide product for chronic weight management — the first FDA-approved oral GLP-1 medication specifically for weight loss. Patients seeking the FDA-approved brand-name Oral Wegovy® obtain it through a retail pharmacy. Weight Method does not dispense or prescribe brand-name Oral Wegovy®. Weight Method's compounded semaglutide program is dispensed by U.S.-licensed 503A compounding pharmacies at $154/month all-inclusive. Compounded semaglutide is not FDA-approved.

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.

Starting at$199/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Compounded semaglutide. Once-weekly subcutaneous injection.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Compounded tirzepatide. Dual-action GLP-1/GIP, once-weekly subcutaneous injection.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Oral Wegovy and injectable Wegovy both contain semaglutide and are FDA-approved for chronic weight management. The key difference is the administration route: a daily pill vs. a weekly injection. Your Weight Method provider will help determine the appropriate compounded semaglutide formulation for your goals during your consultation.

Rybelsus is FDA-approved for type 2 diabetes at doses up to 14mg daily, while Oral Wegovy is FDA-approved for chronic weight management at higher doses (25mg and 50mg daily). Oral Wegovy uses a higher-dose oral semaglutide formulation. Your Weight Method provider will help determine which compounded semaglutide approach fits your goals.

Take Oral Wegovy once daily on an empty stomach with a small amount of plain water, at least 30 minutes before your first food, drink, or other oral medication of the day. This ensures proper absorption of the semaglutide. Your Weight Method provider will start you at the 25mg dose and may increase to 50mg based on your response and tolerability.

Oral Wegovy is FDA-approved as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity. It is a once-daily oral semaglutide tablet. Your Weight Method provider will discuss what to expect from an individualized compounded semaglutide plan.

The side effect profile is similar to other semaglutide products: nausea, diarrhea, vomiting, constipation, and abdominal discomfort are the most common, primarily during the initial weeks and dose adjustments. The OASIS trials showed a similar incidence and severity of GI side effects compared to injectable semaglutide. Starting at 25mg and escalating to 50mg helps manage tolerability.

Weight Method offers oral semaglutide treatment at $154/month with no insurance required. This pricing includes your medication, licensed provider consultation, personalized dosing, ongoing monitoring, and free delivery to your home. Weight Method makes this newest oral GLP-1 option accessible without the high retail pharmacy costs.

Oral Wegovy is ideal for adults with a BMI of 30+ (or 27+ with a weight-related health condition) who want the full efficacy of GLP-1 therapy without injections. It is particularly suited for patients with needle aversion, frequent travelers, or those who simply prefer taking a daily pill. Take the Weight Method quiz to determine if Oral Wegovy is right for you in under two minutes.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

More about Oral Wegovy

Oral Wegovy Side EffectsOral Wegovy ResultsOral Wegovy Dosingsemaglutide Dosage Calculator

Generic Medication

Semaglutide

Other Semaglutide Brands

OzempicWegovyRybelsusSemaglutide

Compare Oral Wegovy

Rybelsus vs Oral WegovyOral Wegovy vs Wegovy

Oral Wegovy by State

Oral Wegovy in AlabamaOral Wegovy in AlaskaOral Wegovy in ArizonaOral Wegovy in ArkansasOral Wegovy in CaliforniaOral Wegovy in Colorado